St. Davids South Austin Medical Center

Austin, Texas 78745

11 studies enrolling now · 32 studies all time

What they study most

ALL, Adult and Pediatric, AML, AML, Adult, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, B Cell ALL, CLL (Chronic Lymphocytic Leukemia), COVID-19

Studies at this site

• A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease — Recruiting now
• A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy — Recruiting now
• A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma — Recruiting now
• A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation — Recruiting now
• A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation — Recruiting now
• Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy — Recruiting now
• Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) — Recruiting now
• A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) — Recruiting now
• A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma — Running, not enrolling
• A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma — Running, not enrolling
• A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies — Running, not enrolling
• Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) — Completed
• HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide — Running, not enrolling
• Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) — Running, not enrolling
• Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma — Completed
• Expanded Access Program for OOS Obe-cel — Available (expanded access)
• Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma — Available (expanded access)
• A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment — Completed
• HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis — Running, not enrolling
• Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma — Running, not enrolling
• GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease — Stopped early
• Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome — Stopped early
• Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells — Enrolling by invitation
• Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma — Stopped early
• A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies — Withdrawn before enrolling
• Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma — Completed
• A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia — Stopped early
• Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk — Completed
• FT538 in Subjects With Advanced Hematologic Malignancies — Stopped early
• ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD — Stopped early
• Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19 — Stopped early
• Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) — APPROVED_FOR_MARKETING